STAT+: Medicare takes another swing at 340B cuts to hospitals

How the 340B Drug Pricing Program Shifts Tax Burden to Local Communities Through Hospital Expansion

The article examines how the 340B Drug Pricing Program, originally designed to subsidize safety-net healthcare for low-income patients, has

CMS Acts to Strengthen Care Quality, Cut Drug Costs, and Slash Out-of-Pocket Expenses for Medicare Beneficiaries

CMS Proposed Rule Locks in Lower Prices and Fosters Innovation for the Medicare Drug Price Negotiation Program

CMS Takes Bold New Approach to Stewarding Medicaid Demonstration Project Spending

Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns

Starmer's US pharma deal criticized as costly threat to NHS funding and public health

Aditya Chakrabortty argues that Keir Starmer's government has pushed through a law enabling a US pharma deal that will harm the NHS by costi